David Passov and Alexander Kutermin to Present on Russia, Ukraine, Belarus and The Baltics as Top Enrolling Regions in a Global Phase 3 Oncology Trial
SAN FRANCISCO, Oct. 18, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov and Manager of Clinical Operations Alexander Kutermin will speak at Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference, November 3-4, in Philadelphia, PA.
According to the International Agency for Research on Cancer's (a division of the World Health Organization) GLOBOCAN 2008 report, an estimated 12.7 million people worldwide are diagnosed with some form of cancer annually and this number is expected to jump to 21 million by 2030. The emerging markets of Russia, Ukraine, Belarus and the Baltics offer access to a population of more than five million cancer sufferers. By conducting clinical trials in these regions, biopharmaceutical companies can significantly speed enrollment, and thereby, reduce the overall time and cost to develop an oncology drug.
During the presentation scheduled for Friday, November 4 at 1:30 p.m., Mr. Passov will explore perceptions and comparisons of emerging markets and discuss how to navigate cultural and regulatory challenges in the region in order to optimize recruitment. Mr. Kutermin will present a case study revealing how Russia, Ukraine, Belarus and the Baltics outperformed 20+ other countries in a global, Phase III breast cancer trial.
Through a series of keynote regional presentations, case studies and interactive panel discussions, Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference will examine the current role that emerging regions play in conducting oncology clinical trials with a focus on the operational, regulatory and logistical challenges involved.
About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.
SOURCE ClinStar, LLC